ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,067.00
-1.24%
S&P ASX All Technology
3,766.30
-0.74%
Brent Oil
72.71
0.45%
US Dollar vs AUD
1.5967
-0.50%
Bitcoin
97,037.96
-0.43%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arbutus Biopharma Corporation (ABUS) Share Price

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

NASDAQ
3.215
0.005
( 0.16% )
Updated: 05:56:26
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.215
Bid
3.21
Offer
3.22
Volume
464,666
3.16 Day's Range 3.255
2.199 52 Week Range 4.725
Market Cap
609.216M
Previous Close
3.21
Open
3.18
Last Trade
1
@
3.22
Last Trade Time
05:59:22
Financial Volume
US$ 1,483,515
VWAP
3.1926
Average Volume (3m)
829,732
Shares Outstanding
189,491,685
Dividend Yield
-
PE Ratio
-8.30
Earnings Per Share (EPS)
-0.38
Revenue
18.14M
Net Profit
-72.85M

About Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tekmirapharm.com
Headquarters
Burnaby, British Columbia, Can
Founded
-
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was US$3.21. Over the last year, Arbutus Biopharma shares have traded in a share price range of US$ 2.199 to US$ 4.725.

Arbutus Biopharma currently has 189,491,685 shares in issue. The market capitalisation of Arbutus Biopharma is US$608.27 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.30.

Ask ADVFN Intelligence (AI)

ABUS Latest News

More News

Form EFFECT - Notice of Effectiveness

06 December 2024
Edgar (US Regulatory)

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio Urges Arbutus to Commit to No...

04 December 2024
Business Wire

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

26 November 2024
GlobeNewswire Inc.

Form 8-K - Current report

16 November 2024
Edgar (US Regulatory)

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...

16 November 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 November 2024
Edgar (US Regulatory)

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

14 November 2024
GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933

07 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 November 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.315-8.923512747883.533.6053.137991043.36155842CS
4-0.285-8.142857142863.53.793.137792663.49902834CS
12-0.745-18.81313131313.964.34913.138297323.75340517CS
260.2157.1666666666734.7252.91510141353.78941877CS
521.00545.47511312222.214.7252.19910609023.30207196CS
156-0.955-22.90167865714.174.7251.6910954262.91036411CS
2600.96542.88888888892.2590.8821371033.71697624CS

ABUS - Frequently Asked Questions (FAQ)

What is the current Arbutus Biopharma share price?
The current share price of Arbutus Biopharma is US$ 3.215
How many Arbutus Biopharma shares are in issue?
Arbutus Biopharma has 189,491,685 shares in issue
What is the market cap of Arbutus Biopharma?
The market capitalisation of Arbutus Biopharma is USD 608.27M
What is the 1 year trading range for Arbutus Biopharma share price?
Arbutus Biopharma has traded in the range of US$ 2.199 to US$ 4.725 during the past year
What is the PE ratio of Arbutus Biopharma?
The price to earnings ratio of Arbutus Biopharma is -8.3
What is the cash to sales ratio of Arbutus Biopharma?
The cash to sales ratio of Arbutus Biopharma is 33.33
What is the reporting currency for Arbutus Biopharma?
Arbutus Biopharma reports financial results in USD
What is the latest annual turnover for Arbutus Biopharma?
The latest annual turnover of Arbutus Biopharma is USD 18.14M
What is the latest annual profit for Arbutus Biopharma?
The latest annual profit of Arbutus Biopharma is USD -72.85M
What is the registered address of Arbutus Biopharma?
The registered address for Arbutus Biopharma is 100, 8900 GLENLYON PARKWAY, GLENLYON BUSINESS PARK, BURNABY, BRITISH COLUMBIA, V5J 5J8
What is the Arbutus Biopharma website address?
The website address for Arbutus Biopharma is www.tekmirapharm.com
Which industry sector does Arbutus Biopharma operate in?
Arbutus Biopharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.0701
(201.49%)
114.36M
EDBLEdible Garden AG Inc
US$ 0.2983
(105.16%)
276.82M
NVNINVNI Group Ltd
US$ 4.82
(80.52%)
38.05M
TPICTPI Composites Inc
US$ 2.0901
(71.32%)
16.28M
OPTXSyntec Optics Holdings Inc
US$ 3.295
(69.85%)
28.59M
CYNCYNGN Inc
US$ 0.4392
(-72.72%)
22.47M
MTEMMolecular Templates Inc
US$ 0.1419
(-59.46%)
6.79M
PRFXPainReform Ltd
US$ 4.7639
(-57.31%)
2.32M
GALTGalectin Therapeutics Inc
US$ 0.9199
(-54.01%)
7.76M
FNGRFingerMotion Inc
US$ 1.19
(-40.50%)
3.11M
APTOAptose Biosciences Inc
US$ 0.26
(52.76%)
290.75M
EDBLEdible Garden AG Inc
US$ 0.299231
(105.80%)
276.85M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.596901
(4.72%)
228.27M
RGTIRigetti Computing Inc
US$ 9.7597
(30.65%)
171.01M
NVDANVIDIA Corporation
US$ 134.355
(2.81%)
159.39M

ABUS Discussion

View Posts
db7 db7 1 month ago
nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944
👍️0
db7 db7 1 month ago
2 days to AASLD...
👍️0
mick mick 2 months ago
👍️0
db7 db7 2 months ago
2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data
👍️0
mick mick 3 months ago
https://www.stockscores.com/charts/charts/?ticker=ABUS
👍️0
mick mick 3 months ago
ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT
👍️0
db7 db7 3 months ago
breaking out; dare i say 'someone' knows 'something'(?)
👍️0
db7 db7 4 months ago
ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"
👍️0
db7 db7 4 months ago
ABUS over $4
👍️0
Monksdream Monksdream 4 months ago
ABUS under $4
👍️0
DewDiligence DewDiligence 5 months ago
ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.
👍️0
Rockurstocks Rockurstocks 5 months ago
Not for long! $ABUS$
👍️0
Monksdream Monksdream 5 months ago
ABUS under $4
👍️0
mick mick 5 months ago
ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT
👍️0
Monksdream Monksdream 5 months ago
ABUS new 52/week high
👍️0
db7 db7 5 months ago
👍️0
db7 db7 6 months ago
https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt
👍️0
db7 db7 7 months ago
New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852
👍️0
db7 db7 7 months ago
Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf
👍️0
mick mick 7 months ago
ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes
👍️0
db7 db7 7 months ago
EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"
👍️0
db7 db7 7 months ago
Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value
👍️0
db7 db7 7 months ago
issue here, now, might be too many open $3 calls? will mm's hold her under....
👍️0
db7 db7 7 months ago
mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price
👍️0
MWM MWM 7 months ago
Nice!
👍️0
db7 db7 7 months ago
https://www.businesswire.com/news/home/20240517970994/en/
👍️0
db7 db7 7 months ago
from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."
👍️0
Monksdream Monksdream 8 months ago
ABUS under $3
👍️0
mick mick 8 months ago
TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:
👍️0
Monksdream Monksdream 9 months ago
ABUS new 52 hi
👍️0
db7 db7 9 months ago
looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june
👍️0
mick mick 9 months ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 9 months ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 9 months ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 9 months ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 9 months ago
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 9 months ago
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
Paullee Paullee 9 months ago
07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
👍️0
MWM MWM 9 months ago
Watching all 3 stocks. $ABUS is kind of moving...
👍️0
db7 db7 9 months ago
was going to take all '3' to explode imo..
👍️0
MWM MWM 9 months ago
Yes, I'm trying to read it myself
👍️0
db7 db7 9 months ago
decision is out; looks like arbutus won '2' and moderna '1' .. please confirm
👍️0
db7 db7 9 months ago
https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/
👍️ 1
Desert dweller Desert dweller 10 months ago
My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.
👍️ 1
Desert dweller Desert dweller 10 months ago
Handle on twitter is @DesertDweller93
👍️0
MWM MWM 10 months ago
Great post!

What’s your handle on Twitter?
👍️0
Desert dweller Desert dweller 10 months ago
I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.
👍️0
MWM MWM 10 months ago
A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s
👍️0
db7 db7 10 months ago
yes, quite the drop yesterday and today on mrna... g/l!
👍️0
MWM MWM 10 months ago
Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...
👍️0

Your Recent History

NASDAQ
ABUS
Arbutus Biopharma
BIT
F34744
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads